2021 is an innovative and foundational year for MVision AI. We are proud of what we have accomplished so far and super excited about what is in store for us in the future. One feeling that stands out as we look back at 2021 is gratitude. We thank everyone who has supported us this year in making our vision to create a better solution and improve the lives of cancer patients a reality.
Successful Beginnings
2021 started with success, as we obtained the CE marking for lymph nodes. There are approximately 500-600 lymph nodes in the human body. Typically, clinicians have drawn lymph nodes with all lymph levels by hand. With the ability to contour lymph nodes, we enter an era where AI algorithms help clinicians in every contouring step of treatment planning.
“The lymph node release indeed marks a new era, and I am extremely proud of our team for making it happen especially in the middle of the current circumstances“, said Mahmudul Hasan, co-founder and CEO of MVision AI.
MVision AI in the UK
In mid-June, we announced our new partnership in the UK and Ireland (with Xiel Ltd.), and many hospitals are benefiting from our guideline-compliant AI segmentation, GCAIS™, radiotherapy software. Five hospitals in NHS England’s Operational Delivery Networks in East Midland (including Northampton and Nottingham) have selected our state-of-the-art, auto-segmentation into their radiotherapy workflow because of our:
- High-quality software
- Number of ROIs
- Consistent compliance with consensus guidelines, including SABR
- And much more
This is vital since many patients in the UK wait up to 2 months (62 days) from the initial referral to the start of radiotherapy treatment. A recent study conducted in the UK found that every month of delay in cancer treatment raised a patient’s risk of death by 6-13%. Using GCAIS™, patients have had access to quality, consistent, and timely radiotherapy treatment.
Summer 2021
Summer was a season of innovation. In early June, we announced our latest GCAIS™ service update, 1.2.1. The update included additions to existing models and 2 new segmentation models:
- The advanced lung CT model following the lung SABR protocol
- The male pelvis MRI model for MRI-only treatment planning workflow, supporting major MRI scanners
Following the update, we were delighted to attend two terrific conferences: the German Society of Radiation Oncology (DEGRO), and the European Society for Radiotherapy and Oncology (ESTRO in Madrid). With our Spanish partnership (DTA, S.L.), Spanish clinics already have access to our excellent radiotherapy solution.
German and Swiss-Trusted GCAIS™
We gained traction in Germany, as German hospitals are implementing our auto-segmentation tool. The University Hospital Cologne and The Charité – Universitätsmedizin Berlin, one of Europe’s largest and well known university hospitals, are using our GCAIS™ software.
Since we announced our partnership in Switzerland (with intellimed) over the Summer, our software has exceeded the expectations of Swiss hospitals, including Hopital de la Tour (a private Swiss hospital).
“We save significant time in target delineation by having the lymph nodes already defined. The high-quality generated contours also bring confidence in plan evaluation, decreasing inter-observer variability in OAR contouring,” said Dr. Ambroise Champion, Radiation Oncologist, and Radiation Therapist at Hopital de la Tour.
Autumn 2021
In Autumn, we experienced great growth: hiring new MVisionary employees and expanding our radiotherapy solution. In mid-autumn, our partnership with Aquilab in France, was publicized. French hospitals are amazed by our consistency and efficiency, selecting our radiotherapy solution without hesitation. We also announced our partnerships with Seres Medical in Turkey and YourRad AB in the Nordic region, increasing patients’ access to GCAIS™ across Europe. In celebration of our Nordic partnership, we published a compact case study with Docrates, a Finnish private hospital, providing high-quality and prompt cancer care with the latest technologies.
Timo Kiljunen, PhD, Adj. Prof., Hospital Physicist at Docrates said, “I have spoken to many colleagues in the field of medicine about how cancer treatment has increased the backlog of patients waiting to receive cancer treatment. Many hospitals throughout Europe and the world are overworked and unable to provide treatment to patients promptly. I am pleased to say that Docrates has been able to provide consistent, timely, and guideline compliant radiotherapy treatment both before and during the COVID 19 pandemic with the help of MVision AI.”
We participated in incredible events: the Joint Medical Physics Conference of ÖGMP, DGMP and SGSMP, the American Society for Radiation Oncology (ASTRO) in Chicago, and Sädehoitopäivät in Helsinki, raising awareness of GBAIS™ transcontinentally.
Concluding 2021
In early December, our CEO and co-founder, Mahmudul Hasan, attended SLUSH (a tech and start-up gathering in Helsinki). Our team is gearing up for more growth as we announced our partnership with MedRon Medical Systems in Canada (pending approval from Health Canada), and are pending FDA clearance. Stay tuned for more exciting announcements in early 2022, as we continue to provide the highest quality, guideline-based AI segmentation, GBAIS™, radiotherapy software.
The MVisionaries wish you a fantastic 2022!
Are you eager to learn more about GCAIS™? Request a demo here.
MVision AI is active on LinkedIn, Twitter, Facebook, and Instagram. Follow us on social media and subscribe to our newsletter to stay up-to-date on the latest MVision AI news.
Welcome you to contact MVision AI:
c/o Terkko Health Hub, Haartmaninkatu 4, 00290 Helsinki, Finland.
Tel: +358 (0) 40 5489 229
Website: https://www.mvision.ai
Email: info@mvision.ai
For media inquiries:
Tel: +358 40 500 7915
Email: pr@mvision.ai
